SELARSDI Trademark

Trademark Overview

On Monday, June 27, 2022, a trademark application was filed for SELARSDI with the United States Patent and Trademark Office. The USPTO has given the SELARSDI trademark a serial number of 97477128. The federal status of this trademark filing is STATEMENT OF USE - TO EXAMINER as of Saturday, January 3, 2026. This trademark is owned by Teva Pharmaceuticals USA. The SELARSDI trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of auto-immune disease
selarsdi

General Information

Serial Number97477128
Word MarkSELARSDI
Filing DateMonday, June 27, 2022
Status748 - STATEMENT OF USE - TO EXAMINER
Status DateSaturday, January 3, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 16, 2023

Trademark Statements

Goods and ServicesPharmaceutical preparations for the treatment of auto-immune disease

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, July 14, 2022
Primary Code005
First Use Anywhere DateFriday, February 21, 2025
First Use In Commerce DateFriday, February 21, 2025

Trademark Owner History

Party NameTeva Pharmaceuticals USA
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054
Party NameTeva Pharmaceuticals USA
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events

Event DateEvent Description
Thursday, June 30, 2022NEW APPLICATION ENTERED
Thursday, July 14, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, February 22, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, February 22, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, February 22, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, February 22, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, April 11, 2023ASSIGNED TO EXAMINER
Tuesday, April 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 26, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, May 4, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, May 4, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, May 4, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 16, 2023PUBLISHED FOR OPPOSITION
Tuesday, May 16, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 11, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, January 4, 2024SOU TEAS EXTENSION RECEIVED
Thursday, January 4, 2024SOU EXTENSION 1 FILED
Thursday, January 4, 2024SOU EXTENSION 1 GRANTED
Saturday, January 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 10, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, July 10, 2024SOU EXTENSION 2 FILED
Wednesday, July 10, 2024SOU EXTENSION 2 GRANTED
Wednesday, July 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 18, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, December 18, 2024SOU EXTENSION 3 FILED
Thursday, December 19, 2024SOU EXTENSION 3 GRANTED
Monday, March 3, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 30, 2025TEAS STATEMENT OF USE RECEIVED
Saturday, January 3, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, June 30, 2025USE AMENDMENT FILED
Saturday, January 3, 2026STATEMENT OF USE PROCESSING COMPLETE

Related Keywords

selarsdi immune disease auto treatment preparations pharmaceutical